[go: up one dir, main page]

MX2018015069A - Composiciones bajo la forma de solución acuosa inyectable que comprende glucagón humano y co-poliaminoacido estadístico. - Google Patents

Composiciones bajo la forma de solución acuosa inyectable que comprende glucagón humano y co-poliaminoacido estadístico.

Info

Publication number
MX2018015069A
MX2018015069A MX2018015069A MX2018015069A MX2018015069A MX 2018015069 A MX2018015069 A MX 2018015069A MX 2018015069 A MX2018015069 A MX 2018015069A MX 2018015069 A MX2018015069 A MX 2018015069A MX 2018015069 A MX2018015069 A MX 2018015069A
Authority
MX
Mexico
Prior art keywords
aqueous solution
compositions
injectable aqueous
human glucagon
copolyamino acid
Prior art date
Application number
MX2018015069A
Other languages
English (en)
Inventor
Soula Olivier
Geissler Alexandre
LAAGE Ségolène
Duracher David
MEIFFREN Grégory
Original Assignee
Adocia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR1655221A external-priority patent/FR3052071B1/fr
Priority claimed from FR1750221A external-priority patent/FR3061660B1/fr
Application filed by Adocia filed Critical Adocia
Publication of MX2018015069A publication Critical patent/MX2018015069A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La invención se refiere así a composiciones físicamente estables bajo la forma de una solución acuosa inyectable, cuyo pH está entre 6.0 y 8.0, y comprende al menos: a) glucagón humano y b) un co-poliaminoácido que lleva cargas de carboxilato y radicales hidrofóbicos Hy. En una modalidad, las composiciones según la invención comprenden además una hormona gastrointestinal.
MX2018015069A 2016-06-07 2017-06-07 Composiciones bajo la forma de solución acuosa inyectable que comprende glucagón humano y co-poliaminoacido estadístico. MX2018015069A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR1655221A FR3052071B1 (fr) 2016-06-07 2016-06-07 Compositions sous forme d'une solution aqueuse injectable comprenant du glucagon et un co-polyaminoacide
FR1750221A FR3061660B1 (fr) 2017-01-10 2017-01-10 Compositions sous forme d'une solution aqueuse injectable comprenant du glucagon humain et un co-polyaminoacide
PCT/EP2017/063887 WO2017211917A1 (fr) 2016-06-07 2017-06-07 Compositions sous forme d'une solution aqueuse injectable comprenant du glucagon humain et un co-polyaminoacide statistique

Publications (1)

Publication Number Publication Date
MX2018015069A true MX2018015069A (es) 2019-05-09

Family

ID=59021507

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018015070A MX2018015070A (es) 2016-06-07 2017-06-07 Composiciones en forma de solucion acuosa inyectable, que comprende glucagon humano y un co-poliaminoacido injertado en el extremo.
MX2018015069A MX2018015069A (es) 2016-06-07 2017-06-07 Composiciones bajo la forma de solución acuosa inyectable que comprende glucagón humano y co-poliaminoacido estadístico.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2018015070A MX2018015070A (es) 2016-06-07 2017-06-07 Composiciones en forma de solucion acuosa inyectable, que comprende glucagon humano y un co-poliaminoacido injertado en el extremo.

Country Status (11)

Country Link
US (2) US10383918B2 (es)
EP (2) EP3463294B1 (es)
JP (2) JP2019521107A (es)
KR (2) KR20190025905A (es)
CN (2) CN109562063A (es)
AU (2) AU2017277589A1 (es)
BR (2) BR112018075259A2 (es)
CA (2) CA3026802A1 (es)
MX (2) MX2018015070A (es)
SG (2) SG11201810939PA (es)
WO (2) WO2017211918A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3083089A1 (fr) * 2018-06-29 2020-01-03 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
US11129877B2 (en) 2017-12-07 2021-09-28 Adocia Compositions in the form of an injectable aqueous solution comprising amylin, an amylin agonist receptor or an amylin analogue and a co-polyamino acid
WO2019110837A1 (fr) * 2017-12-07 2019-06-13 Adocia Compositions sous forme d'une solution aqueuse injectable comprenant du glucagon humain et un co-polyaminoacide
FR3083087A1 (fr) * 2018-06-29 2020-01-03 Adocia Compositions sous forme d'une solution aqueuse injectable comprenant du glucagon humain et un co-polyaminoacide
FR3083086A1 (fr) * 2018-06-29 2020-01-03 Adocia Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide
EP3731858A1 (fr) * 2017-12-07 2020-11-04 Adocia Compositions sous forme d'une solution aqueuse injectable comprenant du glucagon humain et un co-polyaminoacide
CN111836616B (zh) 2017-12-07 2024-01-16 阿道恰公司 包含至少一种pi在5.8与8.5之间的基础胰岛素和带有羧酸根电荷及疏水基的共聚氨基酸的ph 7为7的可注射溶液
EP3740195A1 (fr) 2017-12-07 2020-11-25 Adocia Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide
SG11202005320VA (en) 2017-12-07 2020-07-29 Adocia Compositions in the form of an injectable aqueous solution comprising human glucagon and a copolyamino acid
IL275146B2 (en) 2017-12-07 2025-01-01 Adocia Preparations in the form of an aqueous solution for injection comprising amylin, an amylin receptor agonist or an amylin analog and a copolyamino acid
JP7637965B2 (ja) 2017-12-07 2025-03-03 アドシア ５．８～８．５のｐＩを有する少なくとも１つの基礎インスリンならびにカルボキシレート電荷および疎水性ラジカルを有するコポリアミノ酸を含むｐＨ７の注射溶液
WO2019115411A1 (fr) * 2017-12-07 2019-06-20 Adocia Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide
US20190275110A1 (en) * 2017-12-07 2019-09-12 Adocia Compositions in the form of an injectale aqueous solution comprising human glucagon and a co-polyamino acid
CN108174843B (zh) * 2018-01-24 2018-11-13 广州市进德生物科技有限公司 一种胰高血糖素保护剂及其应用
FR3084584B1 (fr) * 2018-08-03 2020-11-06 Adocia Solution injectable a ph 7 comprenant du glucagon humain et un compose amphiphile porteur de radicaux hydrophobes
EP4144362A1 (en) 2021-09-06 2023-03-08 Adocia Compositions comprising short-acting hormones for treating or preventing obesity and pumps comprising said composition
EP4091625A1 (en) 2021-05-22 2022-11-23 Adocia Compositions comprising short-acting hormones for treating or preventing obesity and pumps comprising said composition
WO2022248419A2 (en) 2021-05-22 2022-12-01 Adocia Compositions comprising short-acting hormones for treating or preventing obesity and pumps comprising said composition

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1202607A (en) * 1968-01-10 1970-08-19 Novo Terapeutisk Labor As Improvements in or relating to stable glucagon solutions and their preparation
ATE269103T1 (de) 1998-03-13 2004-07-15 Novo Nordisk As Stabilisierte wässerige glukagonlösungen enthaltend detergenzien
FR2801226B1 (fr) 1999-11-23 2002-01-25 Flamel Tech Sa Suspension colloidale de particules submicroniques de vectorisation de principes actifs et son mode de preparation
FR2840614B1 (fr) 2002-06-07 2004-08-27 Flamel Tech Sa Polyaminoacides fonctionnalises par de l'alpha-tocopherol et leurs applications notamment therapeutiques
FR2881140B1 (fr) * 2005-01-27 2007-04-06 Flamel Technologies Sa Copolyhydroxyalkylglutamines fonctionnalises par des groupements hydrophobes et leurs applications notamment therapeutiques
FR2902007B1 (fr) * 2006-06-09 2012-01-13 Flamel Tech Sa Formulations pharmaceutiques pour la liberation prolongee de principe(s) actif(s) ainsi que leurs applications notamment therapeutiques
FR2915683B1 (fr) * 2007-05-03 2009-08-07 Flamel Technologies Sa Formulations pharmaceutiques auto-precipitantes pour la liberation modifiee de principe actif
US20110097386A1 (en) 2009-10-22 2011-04-28 Biodel, Inc. Stabilized glucagon solutions
WO2011138802A1 (en) 2010-05-07 2011-11-10 Sun Pharma Advanced Research Company Ltd., Injection solution
ES2533601T3 (es) 2010-11-03 2015-04-13 Arecor Limited Nueva composición que comprende glucagón
EP2797585A4 (en) 2011-12-29 2015-10-07 Latitude Pharmaceuticals Inc STABILIZED GLUCAGONNANOULULSIONS
BR112014016889A8 (pt) * 2012-01-09 2017-07-04 Adocia composição sob a forma de uma solução aquosa injetável, sujo ph está compreendido entre 6,0 e 8,0 e, formulação de dose unitária com ph compreendido entre 7 e 7,8
WO2014096440A2 (en) 2012-12-21 2014-06-26 Novozymes Biopharma Dk A/S Composition
EP3082817A4 (en) 2013-12-18 2017-06-21 Aegis Therapeutics, LLC Compositions for drug administration
US9334316B2 (en) 2014-04-11 2016-05-10 Oregon Health & Science University Formulations comprising glucagon

Also Published As

Publication number Publication date
CA3027238A1 (fr) 2017-12-14
CN109562064A (zh) 2019-04-02
US10383918B2 (en) 2019-08-20
US20170348395A1 (en) 2017-12-07
CN109562063A (zh) 2019-04-02
MX2018015070A (es) 2019-05-09
US10485851B2 (en) 2019-11-26
SG11201810901VA (en) 2019-01-30
SG11201810939PA (en) 2019-01-30
CA3026802A1 (fr) 2017-12-14
BR112018075250A2 (pt) 2019-03-12
KR20190026748A (ko) 2019-03-13
WO2017211918A1 (fr) 2017-12-14
EP3463295B1 (fr) 2020-08-05
KR20190025905A (ko) 2019-03-12
AU2017277590A1 (en) 2019-01-24
AU2017277589A1 (en) 2019-01-24
JP2019521107A (ja) 2019-07-25
EP3463294A1 (fr) 2019-04-10
BR112018075259A2 (pt) 2019-03-12
EP3463294B1 (fr) 2020-08-05
JP2019517560A (ja) 2019-06-24
US20170348394A1 (en) 2017-12-07
WO2017211917A1 (fr) 2017-12-14
EP3463295A1 (fr) 2019-04-10

Similar Documents

Publication Publication Date Title
MX2018015069A (es) Composiciones bajo la forma de solución acuosa inyectable que comprende glucagón humano y co-poliaminoacido estadístico.
SA518400596B1 (ar) محلول قابل للحقن عند الرقم الهيدروجيني 7 يشتمل على أنسولين قاعدي واحد على الأقل تتراوح نقطة (pi) التعادل الكهربائي الخاصة به من 5.8 إلى 8.5، و/أو أنسولين وجبات و/أو هرمون قناة هضمية، وحمض بولي أميني
PH12020550828A1 (en) Compositions in the form of an injectable aqueous solution comprising human glucagon and a copolyamino acid
MX2025009746A (es) Solucion inyectable a ph 7 que comprende al menos una insulina basal que tiene un pi de entre 5.8 y 8.5 y un copoliaminoacido con cargas de carboxilato y radicales hidrofobicos
WO2019110797A8 (fr) Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide
MA43187A (fr) Formulations sous-cutanée d'anticorps anti-cd38 et leurs utilisations
MX2022015755A (es) Profarmacos de hormona paratiroidea (pth).
PH12018502714A1 (en) Nicotine particles and compositions
PH12017501486A1 (en) Nasal powder formulation for treatment of hypoglycemia
IL272141A (en) Preparations in the form of an aqueous solution for injection containing at least human insulin A21G and suppressing glucagon activity with a meal
MY174991A (en) Eurycoma longifolia extract and its use in enhancing and/or stimulating immune system
MX2025008231A (es) Composiciones en forma de una solucion acuosa inyectable que comprende amilina, un receptor agonista de amilina o un analogo de amilina y un copoliaminoacido
SG11202005320VA (en) Compositions in the form of an injectable aqueous solution comprising human glucagon and a copolyamino acid
MX2016004328A (es) Inmunopotenciador.
MX2020006670A (es) Composicion acuosa que comprende acido 2-(dimetil-1h-pirazol-1-il) succinico y amoniaco.
ZA201906037B (en) Liquid composition containing pradofloxacin
EA202091387A1 (ru) Композиции в форме инъецируемого водного раствора, содержащие человеческий глюкагон и сополиаминокислоту
EP3777887A4 (en) ALLERGENIC ACTION BOOST WITH HYALURONIC ACID AS AN ACTIVE SUBSTANCE